Reaction
Chronic Graft Versus Host Disease In Intestine reporting signals
As of the last recalculation, Chronic Graft Versus Host Disease In Intestine appears in 184 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 358.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thiotepa | 26 | 358.5 | 359.5 |
| Busulfan | 36 | 321.5 | 322.3 |
| Fludarabine Phosphate | 59 | 249.4 | 249.7 |
| Alemtuzumab | 25 | 169.1 | 169.3 |
| Melphalan | 26 | 150.4 | 150.6 |
| Melphalan Hydrochloride | 26 | 136.4 | 136.6 |
| Sirolimus | 10 | 88.7 | 88.8 |
| Anti-Thymocyte Globulin (Rabbit) | 6 | 86.9 | 87.0 |
| Posaconazole Delayed-Release | 6 | 63.9 | 63.9 |
| Posaconazole | 8 | 58.2 | 58.2 |
| Ruxolitinib | 25 | 45.5 | 45.5 |